Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is an experimental small molecule belonging to the class of organic compounds known as phenylmethylamines. It features a phosphonate group and a sulfonamide moiety, with a molecular formula of C22H31N2O6PS and an average molecular weight of 482.53 g/mol. The drug is not approved for any indication and there are no reported clinical trials or marketed uses. Its mechanism of action, biological targets, developer information, and therapeutic indications are not available in public databases[1][4][6]. It has been referenced in structural biology resources as ligand "059" but lacks further pharmacological characterization.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (2S)-2-[3-(aminomethyl)phenyl]-3-{(S)-hydroxy[(1R)-2-methyl-1-{[(2-phenylethyl)sulfonyl]amino}propyl]phosphoryl}propanoic acid.